• Something wrong with this record ?

Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma

ME. Mostafa, A. Abdelkader, N. Kuroda, D. Pérez-Montiel, A. Banerjee, O. Hes, KA. Iczkowski,

. 2018 ; 34 (-) : 31-35. [pub] 20180110

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19000798

Chromophobe renal cell carcinoma (CRCC) is not amenable to International Society for Urologic Pathology-endorsed nucleolar grading. Novel grading approaches were proposed, but the rarity of adverse pathology hampers their discriminatory value. We investigate simple linear micrometer measurements and a proposed immunostain in CRCCs. 32 patients' CRCCs were studied: 12 adverse cases (stage pT3, recurrence, or metastasis), 15 controls (stage ≤pT2, no recurrence or metastasis after >3 years), and 8 metastases (3 were paired with primary adverse cases). The ratio of greatest dimensions of largest and smallest nuclei, in each of 5 "worst" high-power fields, excluding those with degenerative features, was designated variation in nuclear size (VNS). Percent multinucleate cells (PMC) were also counted. Mouse anti PD-L2 monoclonal antibody immunostaining was performed. Mean VNS measured in adverse primary and control primary tumors were 3.7 ± 0.5 and 2.4 ± 0.4 respectively (P < .001), and 3.4 ± 0.4 for metastases (P < .001). Optimal VNS cut-off was 2.5, with sensitivity and specificity 0.85 and 0.81, respectively. PMCs were 6.0 ± 3.0 for adverse group, 5.7 ± 2.7 for controls, and 4.1 ± 1.6 for metastases (P = NS). PD-L2 could not discriminate adverse versus good primary tumors (χ21.6, P = .2), but was higher in metastases (χ2 6.9, P < .01), or metastases plus adverse primary tumors (χ2 4.8, P = .03), compared to good-pathology primary tumors. In conclusion, VNS is an easily obtained measurement that can predict adverse behavior of chromophobe RCC, and may impart value for needle biopsy reporting and the choice of active surveillance. PD-L2 was elevated in metastases but was less useful for primary tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000798
003      
CZ-PrNML
005      
20190110104039.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.anndiagpath.2018.01.002 $2 doi
035    __
$a (PubMed)29661724
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mostafa, Mohamed E $u Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, United States.
245    10
$a Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma / $c ME. Mostafa, A. Abdelkader, N. Kuroda, D. Pérez-Montiel, A. Banerjee, O. Hes, KA. Iczkowski,
520    9_
$a Chromophobe renal cell carcinoma (CRCC) is not amenable to International Society for Urologic Pathology-endorsed nucleolar grading. Novel grading approaches were proposed, but the rarity of adverse pathology hampers their discriminatory value. We investigate simple linear micrometer measurements and a proposed immunostain in CRCCs. 32 patients' CRCCs were studied: 12 adverse cases (stage pT3, recurrence, or metastasis), 15 controls (stage ≤pT2, no recurrence or metastasis after >3 years), and 8 metastases (3 were paired with primary adverse cases). The ratio of greatest dimensions of largest and smallest nuclei, in each of 5 "worst" high-power fields, excluding those with degenerative features, was designated variation in nuclear size (VNS). Percent multinucleate cells (PMC) were also counted. Mouse anti PD-L2 monoclonal antibody immunostaining was performed. Mean VNS measured in adverse primary and control primary tumors were 3.7 ± 0.5 and 2.4 ± 0.4 respectively (P < .001), and 3.4 ± 0.4 for metastases (P < .001). Optimal VNS cut-off was 2.5, with sensitivity and specificity 0.85 and 0.81, respectively. PMCs were 6.0 ± 3.0 for adverse group, 5.7 ± 2.7 for controls, and 4.1 ± 1.6 for metastases (P = NS). PD-L2 could not discriminate adverse versus good primary tumors (χ21.6, P = .2), but was higher in metastases (χ2 6.9, P < .01), or metastases plus adverse primary tumors (χ2 4.8, P = .03), compared to good-pathology primary tumors. In conclusion, VNS is an easily obtained measurement that can predict adverse behavior of chromophobe RCC, and may impart value for needle biopsy reporting and the choice of active surveillance. PD-L2 was elevated in metastases but was less useful for primary tumors.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a karcinom z renálních buněk $x patologie $7 D002292
650    _2
$a buněčné jádro $x patologie $7 D002467
650    12
$a velikost buněčného jádra $7 D053145
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a antigeny CD273 $x metabolismus $7 D061027
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Abdelkader, Amrou $u Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, United States.
700    1_
$a Kuroda, Naoto $u Department of Diagnostic Pathology, Kochi Red Cross Hospital, Japan.
700    1_
$a Pérez-Montiel, Delia $u Department of Pathology, Instituto Nacional de Cancerologia, Mexico, D.F., Mexico.
700    1_
$a Banerjee, Anjishnu $u Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States.
700    1_
$a Hes, Ondrej $u Department of Pathology, Charles University, Faculty of Medicine in Plzeň, Czechia.
700    1_
$a Iczkowski, Kenneth A $u Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: kaiczkowski@mcw.edu.
773    0_
$w MED00166541 $t Annals of diagnostic pathology $x 1532-8198 $g Roč. 34, č. - (2018), s. 31-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29661724 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190110104242 $b ABA008
999    __
$a ok $b bmc $g 1363925 $s 1038921
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 34 $c - $d 31-35 $e 20180110 $i 1532-8198 $m Annals of diagnostic pathology $n Ann. diagn. pathol. $x MED00166541
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options